GeoVax Labs Inc (GOVX)

[3DYOGI]

https://www.geovax.com/images/GeoVax_-_GOVX-B11_White_Paper_Feb_2017.pdf

Phase 1 and 2a clinical trials of GOVX-B11: The GOVX-B11 vaccine has been tested at various doses and
regimens by the HVTN in trials involving approximately 500 participants. In these trials, the vaccine has
been extremely well tolerated. In terms of pain and tenderness at the site of inoculation, DNA
inoculations have been indistinguishable from placebo inoculations. Following MVA inoculations, about
70% of participants have transient mild pain, and 25% transient moderate pain at the site of injection.

Figures 8 and 9 depict the excellent response rates for antibody dependent cellular cytotoxicity (ADCC)
elicited by the GOVX-B11 vaccine. In Figure 8, ADCC is measured for gp120. Note the increase in the
response rate with the third MVA boost. The 64% response rate observed here is lower than the 70-90%
response rate observed in RV144. However, the GOVX-B11 elicited response was still scoring at 6
months post the peak vaccine response, whereas the response elicited in RV144 had declined to
undetectable levels by this time (Figure 8). Figure 9 shows an assay where responses score both gp120
and gp41 epitopes exposed during viral entry. Again, the response is highest after the third MVA boost.
The 85% response rate is also higher than the 64% response rate seen for gp120 alone.

Summary: GOVX-B11 is a VLP-expressing DNA/MVA vaccine that elicits a broad-based Ab and T cell
response capable of providing preclinical protection against a heterologous challenge. Based on the
partially successful RV144 trial, the Ab responses elicited by GOVX-B11 have strong features for reducing
the risk of infection. These features include excellent IgG3 to IgA ratios, outstanding durability, multiple
target specificities including the highly conserved immunodominant region of gp41 and excellent activity
in assays for antibody-dependent cellular cytotoxicity. Testing of this vaccine in a pivotal efficacy trial
provides a unique opportunity to identify a vaccine capable of ending the persistence of HIV in the
United States

We are going to wake up one morning trading multi dollars and are life's will be financially well off. And the company we invested in is going to shock the world with a HIV vaccine don't forget all the other pandemic and cancer Immunotherapy vaccines there working on this is a multi billion dollar company in the making.

http://www.voanews.com/a/partially-effective-hiv-vaccine-could-help-turn-corner-on-pandemic/3776689.html

https://www.geovax.com/clinical-pipeline.html

$GOVX